跳至主要内容
临床试验/NCT00002838
NCT00002838已完成1 期

Phase I/II Pilot Study of Allogeneic Peripheral Blood Stem Cell Infusion For Patients With High Risk Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 1995年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
13
试验地点
1
主要终点
Feasibility + Toxicity of Combination Chemotherapy Plus Peripheral Stem Cell Transplantation

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more cancer cells.

PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients with refractory chronic lymphocytic leukemia.

详细描述

OBJECTIVES: I. Determine the feasibility and toxicity of using allogeneic peripheral blood stem cell transplantation after intensive, but non-myeloablative chemotherapy with fludarabine/cyclophosphamide in patients with advanced chronic lymphocytic leukemia. II. Determine the engraftment kinetics and degree of chimerism available with this strategy.

OUTLINE: This is a nonrandomized, dose-seeking study. Stem cell donors receive G-CSF for 4 days prior to and throughout stem cell harvest. Patients receive intensive chemotherapy with fludarabine and cyclophosphamide for 3 days, with patients entered at increasing doses of both drugs until the dose allowing engraftment is determined. Three days after intensive chemotherapy, allogeneic stem cells are infused. Responding patients who do not experience worse than grade 1 acute graft-vs.-host disease receive additional stem cell infusions after 60 and 120 days. Patients are followed monthly for 4 months, at 6 and 12 months, then yearly for 5 years.

PROJECTED ACCRUAL: Up to 25 patients will be entered.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Combination Chemotherapy + PSCT

Experimental

PSCT = Peripheral Stem Cell Transplantation

干预措施: Filgrastim (G-CSF) (Biological)

Combination Chemotherapy + PSCT

Experimental

PSCT = Peripheral Stem Cell Transplantation

干预措施: Cyclophosphamide (Drug)

Combination Chemotherapy + PSCT

Experimental

PSCT = Peripheral Stem Cell Transplantation

干预措施: Fludarabine Phosphate (Drug)

Combination Chemotherapy + PSCT

Experimental

PSCT = Peripheral Stem Cell Transplantation

干预措施: Peripheral Blood Stem Cell Transplantation (Procedure)

结局指标

主要结局

Feasibility + Toxicity of Combination Chemotherapy Plus Peripheral Stem Cell Transplantation

时间窗: Monthly

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验